U.S. Markets closed

United States Triple-Negative Breast Cancer KOL Interview, 2019: Prescribing Habits, Key Marketed Brands, and Late-Phase Pipeline Therapies - ResearchAndMarkets.com

The "Triple-Negative Breast Cancer KOL Interview - US" report has been added to ResearchAndMarkets.com's offering.

A US-based key opinion leader provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple-negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed.

Key pipeline assets highlighted include:

  • balixafortide
  • keytruda
  • sacituzumab govitecan
  • trastuzumab deruxtecan
  • veliparib

For more information about this report visit https://www.researchandmarkets.com/r/d2kmwv

View source version on businesswire.com: https://www.businesswire.com/news/home/20191223005582/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900